These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 24885890

  • 1. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, Carella N, Messa C, Cavallini A, Carr BI.
    BMC Cancer; 2014 May 21; 14():351. PubMed ID: 24885890
    [Abstract] [Full Text] [Related]

  • 2. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.
    Cancer Chemother Pharmacol; 2015 Jun 21; 75(6):1237-1245. PubMed ID: 25907508
    [Abstract] [Full Text] [Related]

  • 3. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C, Refolo MG, D'Alessandro R, Carella N, Messa C, Cavallini A, Carr BI.
    J Exp Clin Cancer Res; 2015 Sep 02; 34(1):90. PubMed ID: 26329608
    [Abstract] [Full Text] [Related]

  • 4. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
    Carr BI, D'Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, Messa C, Cavallini A, Correale M, Di Carlo A.
    J Cell Physiol; 2013 Jun 02; 228(6):1344-50. PubMed ID: 23169148
    [Abstract] [Full Text] [Related]

  • 5. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 02; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 6. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G, Wang M, Hyslop T, Wang Z, Carr BI.
    Int J Cancer; 2010 Dec 15; 127(12):2949-58. PubMed ID: 21351273
    [Abstract] [Full Text] [Related]

  • 7. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.
    Cell Oncol (Dordr); 2018 Jun 15; 41(3):283-296. PubMed ID: 29470830
    [Abstract] [Full Text] [Related]

  • 8. Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates.
    Refolo MG, D'Alessandro R, Lippolis C, Messa C, Carella N, Cavallini A, Carr BI.
    Anticancer Agents Med Chem; 2014 Jun 15; 14(8):1154-60. PubMed ID: 24934165
    [Abstract] [Full Text] [Related]

  • 9. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

  • 11. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y, Jiang H, Gao H, Kong J, Zhang P, Hu S, Shi B, Zhang P, Yao M, Li Z.
    Neoplasia; 2012 Jun 28; 14(6):509-18. PubMed ID: 22787432
    [Abstract] [Full Text] [Related]

  • 12. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
    Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Tafaro A.
    J Cell Physiol; 2013 Feb 28; 228(2):292-7. PubMed ID: 22777740
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 14. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 15. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y, Yan W, Guo L, Meng C, Li B, Neves H, Chen PC, Li L, Huang Y, Kwok HF, Lin Y.
    Mol Med Rep; 2017 Feb 06; 15(2):941-947. PubMed ID: 28035421
    [Abstract] [Full Text] [Related]

  • 16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 06; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 17. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E, Mawrin C.
    Eur J Cancer; 2017 Mar 06; 73():9-21. PubMed ID: 28082204
    [Abstract] [Full Text] [Related]

  • 18. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 19. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 14; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 14; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.